logo-loader
RNS
ProBiotix Health PLC

Probiotix Health PLC - Major new Supply Agreement in the Far East

RNS Number : 7668X
Probiotix Health PLC
20 February 2025
 

20 February 2025

                                                                                                                                 

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

 

Major new Supply Agreement in the Far East

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, is pleased to announce an important new supply agreement in the Far East.

 

ProBiotix has entered into a material and exclusive long-term partnership agreement with Kemin China Technology Co. Ltd ("KCG"). The deal will allow KCG to sell the Company's proprietary probiotic strain LPLDL®,   as a cardiometabolic health supplement ingredient in China, Hong Kong and Macau, with the opportunity to discuss expansion into other regions, driven by Kemin's global commercial operations. ProBiotix will supply its raw materials in bulk to KCG, whereupon LPLDL® will be marketed and sold under a co-branding arrangement. With the Far East being a significant market opportunity for ProBiotix, we will continue to retain the rights to sell finished formats under our own brand or as private label in China.

 

Over 330 million people in China are affected by cardiovascular disease, with two out of five deaths caused by the condition. The Chinese probiotic supplement retail market, was valued in 2024 at $2.3 billion, and is projected to reach $3.6 billion by 2028, a CAGR of 12.8%.

 

The parent company of KCG is Kemin Industries ("Kemin"), a multinational international ingredients supplier. Founded in 1961, Kemin is headquartered in Iowa in the US, has revenues in excess of $1 billion, and has more than 500 patents and applications. As a global leader, Kemin operates in over 120 countries, and from more than 15 manufacturing facilities worldwide. Its nutrition and health activities are focused on providing functional ingredients sourced from plant-based, natural sources for functional drinks, food and supplements.

 

Steen Andersen, CEO of ProBiotix, commented: "With the huge prevalence of cardiovascular disease in China, we are delighted to have secured this important, long-term collaboration with KCG, which should provide a significant and sustainable revenue stream to both companies. It provides scope to expand our sales of LPLDL® in what is a key market for us, through a well-established partner with a strong industry brand. It also complements the recent agreement between ProBiotix and Dancare, who sell and distribute finished products.

 

As confirmed by our recent trading update, we continue to see ongoing momentum in the business and look forward to updating shareholders on our progress."

 

Dr Gan Zhilin, President of KCG, commented: "We are glad to partner with ProBiotix in cardiovascular health to address this global health challenge.

 

Relying on ProBiotix's cutting-edge research in the field of probiotic technology and remarkable achievements in improving cardiovascular health, combined with the rich resources of KCG in the Chinese market, we are committed to providing consumers with more efficient and safer cardiovascular health solutions.

 

This cooperation not only realises the strong combination of technological advantages of both sides, but also the firm practice of our "healthy China" strategy."

 

 

For further information, please contact:

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

 

investors@probiotixhealth.com

Steen Andersen, Chief Executive Officer

Miles Nolan, Investor Relations

 



Peterhouse Capital Limited (Aquis Corporate Adviser and Broker)

 

 

 

Mark Anwyl

Duncan Vasey

 

Tel: 020 7220 9793

 


This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.

 

Notes to Editors:

 

ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.

 

The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXSFDFWUEISEIE
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

4 min read